News | September 20, 2011

ACC Study Shows Health Insurance Levels Can Impact Heart Failure Outcomes

September 20, 2011 — A new study published in the Sept. 27 issue of the Journal of the American College of Cardiology reveals heart failure (HF) patients with Medicaid, Medicare or no insurance have longer hospital stays than those with private/HMO insurance. The under-insured are less likely to receive some of the recommended, evidence-based therapies for HF; they are also 22 percent more likely to die in-hospital.

“People often suspect that source of payment and public funding may be a risk factor for chronic illness and poor outcomes,” said Jack Lewin, M.D., chief executive officer of the American College of Cardiology (ACC). “This study shows it’s not just opinion, but reality. It’s very concerning and critical for Medicaid, Medicare and policymakers to adopt more tools to help prevent HF complications and readmissions. It’s ethically unacceptable and unaffordable not to.”

Researchers analyzed data from nearly 100,000 hospitalized HF patients at 244 sites participating in the Get with the Guidelines Heart Failure quality program between January 2005 and September 2009. They examined pre-specified HF performance and quality-of-care measures applied by the Centers for Medicare and Medicaid Services (CMS) and the Joint Commission; they also studied additional quality indicators, length of hospital stay and in-hospital mortality by payment source.

Even among hospitals participating in a national HF quality improvement program, payment source appears to influence the implementation of guideline-endorsed HF therapy and outcomes. In particular, patients with Medicaid or no health insurance were less likely to receive evidence-based beta blockers or implantable cardioverter defibrillators (ICDs), among other appropriate therapies.

Those covered through Medicaid and Medicare were less frequently prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and beta-blockers.

Based on their findings, authors say interventions are urgently warranted to improve adherence to HF performance and quality-of-care measures. They are also quick to caution the observed associations may be partly explained by differences in socioeconomic status, which may influence patterns of care seeking, care delivery and clinical outcomes.

However, as Lewin points out, these factors do not help to explain the decreased quality of care experienced under Medicare; he says it should be expected to offer comparable treatments to private/HMO coverage. 

Lewin further explains that hospitalization for HF can cost as much as $30,000 in complicated patients, something he suspects a few preventive nursing visits could have avoided in some cases.

Additionally, tracking inpatients and outpatients through registries and other programs like ACC’s Hospital to Home initiative can help ensure quality of care to maximize outcomes early on.

For more information:


Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init